MedGenics Inc., a Vienna, Va.-based developer of a sustained-action therapeutic protein delivery technology for a variety of drugs, has raised Gbp3.28 million in an IPO on the AIM market of the London Stock Exchange. The offering prices MedGenics shares at 10 pence each, for an initial market cap of approximately